Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 + Gemcitabine + Docetaxel in Advanced Lung Cancers
NCT05616624Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2023
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of Pegargiminase in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Recommended phase II dose at 4 weeks, Treatment-related serious adverse event rate at 106 weeks and 1 more. Started Apr 2023; status: terminated.
02
Drugs
Pegargiminase
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05616624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616624.